Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.AVTE · Entity 4757 | CHIEF MEDICAL OFFICER | June 13, 2024 | June 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date June 13, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,602 |
Ending reported balance
After 2024-06-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-06-13 · Exercise / conversion · Acquired 6,000 · Balance 11,602 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Row 2 · 2024-06-13 · Sale · Disposed 6,000 · Balance 5,602 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-04-01 | Direct | 83,510 |
Reported balance
After 2024-06-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-13 · Exercise / conversion · Disposed 6,000 · Balance 83,510 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2: A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
F2: A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2024 Filed Jun 14, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-016993 · form4-06142024_060601.xml · derivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,510 Underlying: Common Stock · 6,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · derivative.exercise_date: A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 6,000 | $24.50 | $147,000.00 |
DisclosureSEC source: 0001415889-24-016993 · form4-06142024_060601.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,602 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 6,000 | $2.14 | $12,840.00 |
DisclosureSEC source: 0001415889-24-016993 · form4-06142024_060601.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| May 17, 2024 Filed May 17, 2024 19:10 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-013630 · form4-05172024_070505.xml · derivative · entry 4 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,324 Underlying: Common Stock · 4,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F4 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| May 17, 2024 Filed May 17, 2024 19:10 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 86 | $21.86 | $1,879.96 |
DisclosureSEC source: 0001415889-24-013630 · form4-05172024_070505.xml · nonDerivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,602 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| May 17, 2024 Filed May 17, 2024 19:10 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,914 | $21.07 | $82,451.54 |
DisclosureSEC source: 0001415889-24-013630 · form4-05172024_070505.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,688 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.605 to $21.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 17, 2024 Filed May 17, 2024 19:10 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 4,000 | $2.14 | $8,560.00 |
DisclosureSEC source: 0001415889-24-013630 · form4-05172024_070505.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · balance_after: Includes 2,351 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d). Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,497 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-24-011251 · form4-04192024_060404.xml · derivative · entry 5 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 539 Underlying: Common Stock · 3,497 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F5 · derivative.exercise_date: A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 503 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-24-011251 · form4-04192024_060404.xml · derivative · entry 4 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,511 Underlying: Common Stock · 503 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F4 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 311 | $23.33 | $7,254.91 |
DisclosureSEC source: 0001415889-24-011251 · form4-04192024_060404.xml · nonDerivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.12 to $23.97, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,689 | $22.30 | $82,266.91 |
DisclosureSEC source: 0001415889-24-011251 · form4-04192024_060404.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,562 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.08 to $22.80, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 4,000 | $1.74 | $6,960.00 |
DisclosureSEC source: 0001415889-24-011251 · form4-04192024_060404.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-009596 · form4-04012024_060401.xml · derivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,510 Underlying: Common Stock · 9,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · derivative.exercise_date: A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 9,000 | $29.50 | $265,500.00 |
DisclosureSEC source: 0001415889-24-009596 · form4-04012024_060401.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 9,000 | $2.14 | $19,260.00 |
DisclosureSEC source: 0001415889-24-009596 · form4-04012024_060401.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-008771 · form4-03202024_060312.xml · derivative · entry 6 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,510 Underlying: Common Stock · 3,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F5 · derivative.exercise_date: A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-24-008771 · form4-03202024_060312.xml · derivative · entry 5 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,036 Underlying: Common Stock · 4,000 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F4 · derivative.exercise_date: A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 613 | $26.40 | $16,184.55 |
DisclosureSEC source: 0001415889-24-008771 · form4-03202024_060312.xml · nonDerivative · entry 4 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.25 to $26.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 6,387 | $25.81 | $164,872.10 |
DisclosureSEC source: 0001415889-24-008771 · form4-03202024_060312.xml · nonDerivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,864 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.25 to $26.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 3,000 | $2.14 | $6,420.00 |
DisclosureSEC source: 0001415889-24-008771 · form4-03202024_060312.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 4,000 | $1.74 | $6,960.00 |
DisclosureSEC source: 0001415889-24-008771 · form4-03202024_060312.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,030 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-007533 · form4-03112024_060304.xml · derivative · entry 4 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,510 Underlying: Common Stock · 8,030 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F3 · derivative.exercise_date: A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 945 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-007533 · form4-03112024_060304.xml · derivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,324 Underlying: Common Stock · 945 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 8,975 | $24.50 | $219,887.50 |
DisclosureSEC source: 0001415889-24-007533 · form4-03112024_060304.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 8,975 | $2.14 | $19,206.50 |
DisclosureSEC source: 0001415889-24-007533 · form4-03112024_060304.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 511 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-24-005571 · form4-02272024_060201.xml · derivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,014 Underlying: Common Stock · 511 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 511 | $19.50 | $9,964.50 |
DisclosureSEC source: 0001415889-24-005571 · form4-02272024_060201.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 511 | $1.74 | $889.14 |
DisclosureSEC source: 0001415889-24-005571 · form4-02272024_060201.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 987 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-24-004903 · form4-02222024_060201.xml · derivative · entry 5 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,036 Underlying: Common Stock · 987 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F5 · derivative.exercise_date: A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,502 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-24-004903 · form4-02222024_060201.xml · derivative · entry 4 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,525 Underlying: Common Stock · 2,502 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F4 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 898 | $20.58 | $18,477.79 |
DisclosureSEC source: 0001415889-24-004903 · form4-02222024_060201.xml · nonDerivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.55 to $20.67, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,591 | $20.11 | $52,096.72 |
DisclosureSEC source: 0001415889-24-004903 · form4-02222024_060201.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,149 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.53 to $20.515, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 3,489 | $1.74 | $6,070.86 |
DisclosureSEC source: 0001415889-24-004903 · form4-02222024_060201.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 66,586 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001774 · form4-01242024_060106.xml · derivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,586 Underlying: Common Stock · 66,586 shares Expires 2034-01-21 F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-24-001609 · form4-01192024_060101.xml · derivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,027 Underlying: Common Stock · 4,000 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4,000 | $19.50 | $78,000.00 |
DisclosureSEC source: 0001415889-24-001609 · form4-01192024_060101.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 4,000 | $1.74 | $6,960.00 |
DisclosureSEC source: 0001415889-24-001609 · form4-01192024_060101.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-017025 · form4-12292023_061202.xml · derivative · entry 4 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,540 Underlying: Common Stock · 100 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F3 · derivative.exercise_date: A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-017025 · form4-12292023_061202.xml · derivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,269 Underlying: Common Stock · 25 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 125 | $24.50 | $3,062.50 |
DisclosureSEC source: 0001415889-23-017025 · form4-12292023_061202.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 125 | $2.14 | $267.50 |
DisclosureSEC source: 0001415889-23-017025 · form4-12292023_061202.xml · nonDerivative · entry 1 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,076 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-016908 · form4-12222023_061202.xml · derivative · entry 4 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,027 Underlying: Common Stock · 1,076 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F3 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,924 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-016908 · form4-12222023_061202.xml · derivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,023 Underlying: Common Stock · 2,924 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · derivative.exercise_date: A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4,000 | $19.50 | $78,000.00 |
DisclosureSEC source: 0001415889-23-016908 · form4-12222023_061202.xml · nonDerivative · entry 2 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,197 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-016539 · form4-12152023_061201.xml · derivative · entry 8 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,306 Underlying: Common Stock · 7,197 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F3 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-016539 · form4-12152023_061201.xml · derivative · entry 7 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,744 Underlying: Common Stock · 2,700 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · derivative.exercise_date: A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 9,897 | $19.50 | $192,991.50 |
DisclosureSEC source: 0001415889-23-016539 · form4-12152023_061201.xml · nonDerivative · entry 4 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 9,897 | $1.74 | $17,220.78 |
DisclosureSEC source: 0001415889-23-016539 · form4-12152023_061201.xml · nonDerivative · entry 3 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,450 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-016539 · form4-12152023_061201.xml · derivative · entry 6 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,503 Underlying: Common Stock · 1,450 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F3 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 653 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-016539 · form4-12152023_061201.xml · derivative · entry 5 Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,444 Underlying: Common Stock · 653 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. F2 · derivative.exercise_date: A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.